Orphazyme A/S

Equities

ORPHA

DK0062502894

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen Other stock markets 05:26:36 2024-04-25 am EDT			5-day change	1st Jan Change
1,100 ^DKK	+2.34%		+0.02%	-17.29%

Mar. 27	Orphazyme A/S Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 04	FDA Extends Review of Zevra's Arimoclomol by Three Months	DJ

Orphazyme A/S Maintains its Outlook for the Full Year 2021

August 31, 2021 at 01:00 am EDT

Orphazyme A/S maintained its outlook for the full year 2021. Net operating loss is anticipated to be in the range of DKK 670 million to DKK 700 million; and the company anticipated reaching net revenues of between DKK 30 and DKK 40 million by year-end December 31, 2021.

Latest news about Orphazyme A/S

Orphazyme A/S Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
FDA Extends Review of Zevra's Arimoclomol by Three Months	Mar. 04	DJ
Orphazyme A/S acquired an additional unknown minority stake in CombiGene AB (OM:COMBI).	Feb. 20	CI
Zevra Therapeutics Refiles Arimoclomol Application With FDA	Dec. 27	DJ
Orphazyme A/S Provides Earnings Guidance for the Full Year 2023	23-09-12	CI
Orphazyme A/S Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-12	CI
Orphazyme A/S Announces Anders Fink Vadsholt to Step Down as CEO	23-05-30	CI
Orphazyme A/S Announces Anders Fink Vadsholt to Step Down as CFO	23-05-30	CI
Orphazyme A/S Provides Earnings Guidance for the Full-Year 2023	23-05-30	CI
Orphazyme A/S Announces Board Changes	23-05-17	CI
Orphazyme A/S Provides Earnings Guidance for the Full-Year 2023	23-04-25	CI
Orphazyme A/S Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-25	CI
Orphazyme A/S(CPSE:ORPHA) added to OMX Nordic Small Cap Index	23-01-03	CI
Orphazyme A/S Reports Earnings Results for the Half Year Ended June 30, 2022	22-09-26	CI
Orphazyme A/S Revises Earnings Guidance for the Year 2022	22-09-25	CI
Orphazyme A/S Announces Board Appointment	22-06-29	CI
Orphazyme A/S Reports Earnings Results for the Full Year Ended December 31, 2021	22-06-07	CI
Orphazyme A/S Provides Earnings Guidance for the Full Year of 2022	22-06-07	CI
Orphazyme Closes $18 Million Sale Of Assets, Business Operations Under Restructuring Plan	22-06-01	MT
KemPharm Denmark A/S acquired Substantially All Assets and Business Activities of Orphazyme A/S for $18 million.	22-05-30	CI
Orphazyme A/S Announces Executive Changes	22-05-23	CI
Orphazyme A/S(CPSE:ORPHA) dropped from S&P Global BMI Index	22-05-20	CI
KemPharm Agrees to Buy Orphazyme for $12.8 Million	22-05-16	MT
KemPharm Denmark A/S agreed to acquire substantially all assets and business activities of Orphazyme A/S for $18 million.	22-05-14	CI
Orphazyme's American Depositary Shares Delisted From Nasdaq	22-04-01	MT

Chart Orphazyme A/S

Duration

Period

More charts

Company Profile

Orphazyme A/S, formerly Orphazyme ApS, is a Denmark-based company active within the biopharmaceutical industry. It develops new therapies for the treatment of a family of genetic disorders. The Company's main focus is on preclinical development of medicines for the treatment of lysosomal storage diseases (LSDs), a group of approximately 50 genetic disorders that result from deficiencies of lysosomal enzymes or other lysosomal components, and protein aggregation diseases. The Companyâs candidate, arimoclomol, stimulates the production of the cellsâ protein rescue system, the heat shock proteins, which helps the misfolded proteins to either get back to their functional shape or, if this cannot be achieved, remove them from the cells by means of the cellsâ recycling system, the lysosomes, so they no longer form toxic aggregates. The Company collaborates with academic institutions in Europe and the United States.

Sector

Biotechnology & Medical Research

Calendar

2024-08-26 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ORPHAZYME A/S	-17.29%	5.44M
VERTEX PHARMACEUTICALS INCORPORATED	-2.26%	104B
REGENERON PHARMACEUTICALS, INC.	+1.41%	97.42B
ARGENX SE	+0.79%	22.2B
BIONTECH SE	-17.84%	21.23B
GENMAB A/S	-11.11%	18.33B
WUXI APPTEC CO., LTD.	-42.83%	16.35B
BEIGENE, LTD.	-17.63%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+4.55%	13.98B
SAREPTA THERAPEUTICS, INC.	+32.11%	11.66B

Bio Therapeutic Drugs